论文部分内容阅读
目的:对低剂量吉西他滨治疗晚期非小细胞肺癌的疗效观察及其对患者肺功能的影响进行分析。方法:选取2013年12月至2015年6月于该院诊治的晚期非小细胞肺癌患者80例,随机分为对照组和低剂量组。对照组采取常规剂量吉西他滨治疗,低剂量组采取低剂量吉西他滨治疗。比较两组临床效果。结果:两组晚期非小细胞肺癌患者的临床疗效无差异(P>0.05),低剂量组患者血液毒性反应发生率优于对照组(P>0.05)。结论:低剂量吉西他滨治疗晚期非小细胞肺癌一定的临床效果,血液毒性反应发生率较低。
Objective: To evaluate the efficacy of low-dose gemcitabine in the treatment of advanced non-small cell lung cancer and its impact on lung function. Methods: Eighty patients with advanced non-small cell lung cancer who were diagnosed and treated in our hospital from December 2013 to June 2015 were randomly divided into control group and low-dose group. The control group took the conventional dose of gemcitabine, and the low dose group took the low dose of gemcitabine. The clinical effects of two groups were compared. Results: There was no difference in the clinical efficacy between the two groups (P> 0.05). The incidence of hematologic toxicity in the low-dose group was better than that in the control group (P> 0.05). Conclusion: The low dose of gemcitabine in the treatment of advanced non-small cell lung cancer has a certain clinical effect, the incidence of hematological toxicity is low.